Recursion Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Recursion Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Recursion Pharmaceuticals Inc recorded a cumulative net loss of $-519 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -38.25%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3798, from total ROA ranking in the first quarter of 2026 at 4562.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-6.89 %	2.63 %	6.43 %	105.89 %	77.85 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-519	-560	-645	-716	-649
Return On Assets (TTM)	-38.25 %	-40.6 %	-47.05 %	-53.08 %	-55.57 %
RXRX's Total Ranking	# 3798	# 4562	# 4043	# 4119	# 4201
Total Assets (TTM) in million	1,213	1,340	1,474	1,400	1,302
Seq. Total Assets Change	-9.47 %	-9.13 %	5.33 %	7.46 %	-0.22 %
Seq. Net Income Change	-	-	-	-	-

RXRX's 5 Years Annual ROA >> Back to RXRX Management Effectiveness >> Compare RXRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 473
Overall	# 3730

Return On Assets Statistics
High	Average	Low
-31.35 %	-44.99 %	-57.28 %
(Mar 31 2022)		(Jun 30 2024)

Financial Statements
Recursion Pharmaceuticals Inc 's Assets	$ 1,213 million	RXRX's Balance sheet
Recursion Pharmaceuticals Inc 's Income	$ -131 million	Quarterly RXRX's Income Statement
RXRX's Income by Division		See RXRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	6.43 %	122.98 %	-7.31 %	9.79 %	-
Total Assets in million	1,474	1,385	621	670	610
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-645	-464	-328	-239	-186
Annual Return On Assets	-43.74 %	-33.48 %	-52.82 %	-35.74 %	-30.55 %

RXRX's 5 Years Annual ROA >> Back to RXRX Management Effectiveness >> Compare RXRX ROA to its Competitors

More Return On Assets Ratios
RXRX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RXRX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RXRX's Competitors
Subscribers only: Roa for Recursion Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for RXRX's Customers

You may also want to know
RXRX's Roi	RXRX's Inventory Turnover Ratio	RXRX's Growth Rates	RXRX's Dividend Comparisons
	RXRX's Profitability Ratios	RXRX's Asset Turnover Ratio	RXRX's Dividend Growth
RXRX's Roe	RXRX's Valuation Ratios	RXRX's Financial Strength Ratios	RXRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-09T00:15:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.